Goldman Sachs Maintains Neutral on Calumet, Raises Price Target to $45
Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ:CLMT) with a Neutral and raises the price target from $40 to $45.
Read original at benzingaStocks · News reference
UBS Maintains Neutral on Calumet, Raises Price Target to $47
UBS analyst Manav Gupta maintains Calumet (NASDAQ:CLMT) with a Neutral and raises the price target from $26 to $47.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 25, 2026, 4:20 PM
- Checked
- Aug 25, 2026, 4:20 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
TD Cowen Maintains Hold on Calumet, Raises Price Target to $40
TD Cowen analyst Jason Gabelman maintains Calumet (NASDAQ:CLMT) with a Hold and raises the price target from $34 to $40.
Read original at benzingaShares of oil and gas refining and marketing companies are trading higher amid energy price gains due to a possible impasse in U.S.-Iran negotiations, with Iran demanding war reparations and unfreezing of assets. Also, reports suggest President Trump is willing to end the war in exchange for reopening Hormuz without addressing Iran's nuclear program, which may lead to concerns over future military tensions.
Read original at benzinga